Concepedia

A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes

Tim Heise, Cees J. Tack, Robert Cuddihy, Jaime A. Davidson, D. Gouet, Andreas Liebl, Enrique Romero, Henriette Mersebach, Patrik Dykiel, Rolf Jorde

Diabetes Care · 2011 · 96 citations · 17 references

DOIFull text

Open access

Abstract

In this proof-of-concept trial, once-daily IDegAsp was safe, well tolerated, and provided comparable overall glycemic control to IGlar at similar low rates of hypoglycemia, but better postdinner plasma glucose control.

References

17

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

The Lancet · 1998 · 19.9K citations

, , +9

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

R. C. Turner, Charles Fox, Matthews et al. · The Lancet · 1998 · 8.4K citations

, , +10

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

The Lancet · 1998 · 8.2K citations

, , +10

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

PubMed · 1998 · 4.3K citations

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

Yasuo Ohkubo, Hideki Kishikawa, Eiichi Araki et al. · Diabetes Research and Clinical Practice · 1995 · 3.1K citations

, , +10